Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors | Zendy

Eva Poveda | Zendy; Carmen de Mendoza | Zendy; Luz MartínCarbonero | Zendy; Angélica Corral | Zendy; Verónica Briz | Zendy; J. Gonzalez-Lahoz | Zendy; Vincent Soriano | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors

Author(s) -

Eva Poveda,

Carmen de Mendoza,

Luz MartínCarbonero,

Angélica Corral,

Verónica Briz,

J. Gonzalez-Lahoz,

Vincent Soriano

Publication year - 2007

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkm276

Subject(s) - darunavir , saquinavir , indinavir , nelfinavir , medicine , ritonavir , amprenavir , lopinavir , drug resistance , virology , atazanavir , genotype , pharmacology , viral load , biology , protease , genetics , human immunodeficiency virus (hiv) , hiv 1 protease , antiretroviral therapy , biochemistry , enzyme , gene

To estimate to what extent darunavir might be effective in patients failing distinct protease inhibitors (PIs), the genotypic resistance scores recently reported for the drug were examined in a large clinical HIV-1 drug resistance database.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research